BLISS GVS PHARMA LTD
Latest filings
Next results: Thu, 29 Oct · Financial Results- Board to approve September 2026 quarterly and half-year results · Results
- Postal ballot notice for appointment of three directors · Compliance
- Postal ballot to appoint 3 new directors nominated by new promoter Anupam Rasayan · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products and recently commenced operations in Kenya. Facilities received a WHO inspection closure report, indicating compliance with WHO manufacturing standards, and reportedly use 55 to 60 percent renewable energy. For FY26, the company reported revenue of Rs 927.11 crore with an EBITDA margin of 25.36 percent. The cost structure is materials-heavy at 41.7 percent of revenue, followed by other operating expenses at 21.7 percent and employee costs at 14.7 percent. A leadership transition took effect in July 2026, with Mr. Rahul Adakmol, previously at Dr. Reddy's, Bharat Serums and Reliance, appointed CEO from July 15, 2026.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BLISS GVS PHARMA LTD's filed financials and exchange disclosures
What does BLISS GVS PHARMA LTD do?
BLISS GVS PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BLISSGVS.
Is BLISS GVS PHARMA LTD profitable?
Yes. Over the trailing twelve months BLISS GVS PHARMA LTD reported a net profit of ₹142 Cr on revenue of ₹1,005 Cr.
Does BLISS GVS PHARMA LTD pay a dividend?
Yes. The dividend yield is 0.16% at the current price. It paid out 8% of its profit as dividend in FY26.
Is BLISS GVS PHARMA LTD debt-free?
On a net basis, yes. It reported borrowings of ₹2.93 Cr on its 31 Mar 2026 balance sheet, but holds ₹32 Cr more cash than debt.
Is BLISS GVS PHARMA LTD expensive compared with its peers?
On trailing P/E, BLISS GVS PHARMA LTD ranks 114 of 158 in Pharmaceuticals — cheaper than 28% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the BLISS GVS PHARMA LTD share price move in a day?
On a typical session BLISS GVS PHARMA LTD moves 1.86% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are BLISS GVS PHARMA LTD's next results?
Financial Results on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track BLISS GVS PHARMA LTD's announcements?
Every NSE and BSE filing by BLISS GVS PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.